Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-Yr results of a randomized, double-blind, placebo-, and active-controlled study

Journal of Bone and Mineral Research

Volumn 23, Issue 4, 2008, Pages 525-535

  Miller, Paul D ^a   Chines, Arkadi A ^b   Christiansen, Claus ^c   Hoeck, Hans C ^c   Kendler, David L ^d   Lewiecki, E Michael ^e   Woodson, Grattan ^f   Levine, Amy B ^b   Constantine, Ginger ^b   Delmas, Pierre D ^g  

^a University of Colorado Health Sciences Center   (United States)

^b PFIZER INC   (United States)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d Osteoporosis Research Centre   (Canada)

^e NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^f Atlanta Research Center   (United States)

^g UNIVERSITÉ DE LYON   (France)

Author keywords

Bazedoxifene; BMD; Osteoporosis; Prevention; Selective estrogen receptor modulator

Indexed keywords

BAZEDOXIFENE; BIOLOGICAL MARKER; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PLACEBO; RALOXIFENE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; HEADACHE; HEART INFARCTION; HIP; HOT FLUSH; HUMAN; HUMAN TISSUE; INFECTION; LEG CRAMP; LUMBAR SPINE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHLEBITIS; POPULATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TIME; VEIN THROMBOSIS;

BONE DENSITY; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 41849138667     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.071206     Document Type: Article

References (45)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
2. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Ragi Eis S, Gennari C, Johnell O, Johnston CC Jr, Lau EM, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Khaltaev N, Miller PD, Mithal A, Murii H, Papapoulos S, Woolf A, Yu W 1999 Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10:259-264.
3. National Osteoporosis Foundation 2006 America's bone health: The state of osteoporosis and low bone mass. Available online at http://www.nof.org/ advocacy/prevalence/indexed.htm. Accessed January 29, 2007.
4. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL 1992 Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005-1010.
5. Greendale GA, Barrett-Connor E, Ingles S, Haile R 1995 Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study. J Am Geriatr Soc 43:955-961.
6. Browner WS, Pressman AR, Nevitt MC, Cummings SR 1996 Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 156:1521-1525.
7. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D 2000 Risk of mortality following clinical fractures. Osteoporos Int 11:556-561.
8. U.S. Department of Health and Human Services 2004 Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Dept of Health and Human Services, Public Health Service, Office of the Surgeon General.
9. Burge RT, King AB, Balda E, Worley D 2003 Methodology for estimating current and future burden of osteoporosis in state populations: Application to Florida in 2000 through 2025. Value Health 6:574-583.
10. Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137.
11. Weitzmann MN, Pacifici R 2006 Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 116:1186-1194.
12. Riggs BL, Khosla S, Melton LJ III 2002 Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
13. Devine A, Dick IM, Dhaliwal SS, Naheed R, Beilby J, Prince RL 2005 Prediction of incident osteoporotic fractures in elderly women using the free estradiol index. Osteoporos Int 16:216-221.
14. Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA III, Berger ML, Santora AC, Sherwood LM 2003 Recency and duration of postmenopausal hormone therapy: Effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause 10:412-419.
15. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544-564.
16. Delmas PD, Rizzoli R, Cooper C, Reginster JY 2005 Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 16:1-5.
17. North American Menopause Society 2006 Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 13:340-367.
18. Komm BS, Lyttle CR 2001 Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 949:317-326.
19. Miller CP, Collini MD, Tran BD, Harris HA, Kharode YP, Marzolf JT, Moran RA, Henderson RA, Bender RH, Unwalla RJ, Greenberger LM, Yardley JP, Abou-Gharbia MA, Lyttle CR, Komm BS 2001 Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 44:1654-1657.
20. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR 2005 Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999-4008.
21. Ronkin S, Northington R, Baracat E, Nunes MG, Archer DF, Constantine G, Pickar JH 2005 Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105:1397-1404.
22. Ronkin S, Baracat E, Roma L, Clarke L, Boudes P, Constantine G, Lindsay R 2001 TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. Endocrine Society program and abstracts of the 83rd Annual Meeting, June 20-23, 2001, Denver, CO, USA.
23. Boudes P, Ronkin S, Korner P, Baracat E, Constantine G 2003 Effects of bazedoxifene TSE-424, a novel tissue selective estrogen receptor modulator SERM, on the incidence of breast pain. Osteoporos Int 14(Suppl 7):S14.
24. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
25. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H III, Gennari C, Christiansen C, Arnaud CD, Delmas PD 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450.
26. Seeman E 2007 Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308-317.
27. Silverman SL, Christiansen C, Genant H, Zanchetta JR, Valter I, deVilliers TJ, Constantine G, Chines AA 2007 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 22:S1;S58.
28. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338:485-492.
29. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
30. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
31. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
32. Delmas PD, Li Z, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337.
33. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
34. Miller CP 2005 Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3:103-110.
35. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
36. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
37. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261.
38. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
39. Seeman E, Delmas PD 2006 Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261.
40. Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ 2002 Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17:1139-1147.
41. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
42. Delmas PD, Seeman E 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 35:1225-1226.
43. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD 2002 Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857.
44. Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr 2004 Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 52:1543-1548.
45. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197.